Partner Or Go It Alone? TG Therapeutics Ponders EU Plans For Briumvi
MS Drug Approved By European Commission
TG Therapeutics has successfully launched Briumvi on its own in the US, despite fierce competition from established same-class MS drugs Ocrevus and Kesimpta, but is still weighing up the pros and cons of partnering for the European market.
You may also be interested in...
A subcutaneous version of Ocrevus is as effective as the intravenous form of Roche's biggest seller, and could boost access of the multiple sclerosis drug where access to intravenous clinics is problematic.
With positive results from a Phase II proof of concept controlled human infection model study evaluating Neumifil under its belt, the Scottish biotech is preparing to put the drug through its paces in a chronic obstructive pulmonary disease trial next year.
The Boston-based biotech is weighing up its options as the fall-out from its failed IPF candidate casts a shadow over Galecto’s future.